LGALS3 and Myocardial fibrosis: The reason for this discrepancy is unknown, but may be related to variations in CRT indications as a result of guideline evolution, inconsistent CRT response criteria based either on left ventricle remodeling (LVESVi > 10% at 6 months14), functional status (6 minute walking test13), morbidity (major cardiovascular outcomes28) or a composite thereof (LVEF > 35% and survival or NT-ProBNP < 1000 pg/ml and survival12), somehow poorly correlated29, and lastly a lack association between histological myocardial fibrosis in human biopsies30 and fibrosis biomarkers such as Galectin-3 and PINP.